Kiora Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Kiora Pharmaceuticals has a total shareholder equity of $34.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $42.4M and $7.5M respectively. Kiora Pharmaceuticals's EBIT is $6.2M making its interest coverage ratio -17.7. It has cash and short-term investments of $31.3M.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | -17.7x |
Cash | US$31.28m |
Equity | US$34.90m |
Total liabilities | US$7.54m |
Total assets | US$42.44m |
Recent financial health updates
Recent updates
Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem
May 21Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Oct 13Kiora Pharma announces 1-for-40 reverse stock split
Sep 26Kiora Pharmaceuticals reports 1H results
Aug 12Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing
Jul 28Kiora Pharmaceuticals prices $5.2M underwritten public offering
Jul 22Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201
Jul 05EyeGate Pharmaceuticals announces $8M private placement
Jan 06EyeGate surge in premarket as it acquires Panoptes Pharma for $4M
Dec 21Financial Position Analysis
Short Term Liabilities: KPRX's short term assets ($33.5M) exceed its short term liabilities ($1.6M).
Long Term Liabilities: KPRX's short term assets ($33.5M) exceed its long term liabilities ($5.9M).
Debt to Equity History and Analysis
Debt Level: KPRX is debt free.
Reducing Debt: KPRX had no debt 5 years ago.
Debt Coverage: KPRX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: KPRX has no debt, therefore coverage of interest payments is not a concern.